Follow Us

The Latest

Promo Image

The Lingering Debate With Abacavir and Heart Disease

The debate continues on the possible increased risk for heart attacks when using Ziagen (abacavir), a result that was first released about 2 years ago. The D:A:D study, which follows the side effects of HIV drugs, earlier reported that the drugs in g...

Promo Image

Ziagen Pills Found in Fake Combivir Packaging

Dear Community Member,

We would like to call to your attention an apparent third-party tampering that caused misbranding of Ziagen® (abacavir sulfate) Tablets as Combivir® (lamivudine and zidovudine) Tablets and employed counterfeit labels for Combi...

Promo Image

Anti-HIV Drugs Update

Several studies of abacavir (Ziagen) were presented at the recent International Conference on AIDS in Durban. Most of the results are preliminary and are based only on interim analysis, but they do extend our knowledge of the use of the drug. They su...

Promo Image

Abacavir vs. Indinavir in Therapy-Naive People (CNA3014)

Preliminary 24-week data was presented of an ongoing trial comparing abacavir to indinavir (taken three times a day). Both regimens include Combivir (zidovudine + 3TC). The 342 treatment-naive people in this trial had viral loads above 5,000 copies, ...

Promo Image

Ziagen (Abacavir): New Warning on Restarting

In July 2000, Glaxo Wellcome sent a letter to physicians warning them to be especially careful when restarting abacavir after it has been discontinued. It has long been known that abacavir must never be re-started after it has been stopped due to a h...

Promo Image

Important Drug Warning: Severe Hypersensitivity Reactions Following Reintroduction With Ziagen (Abacavir Sulfate) Products

Note: This is the retyped text of a letter from Glaxo Wellcome Inc. Contact the company for a copy of any referenced enclosures.

Dear Health Care Provider,

Glaxo Wellcome Inc. is writing to inform you of important new safety information about hyper...

Promo Image

The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir

In this collaborative European study the authors began with the observation that the mutation Q151M, together with other mutations that code on 62, 68, 75, 77 and 116 of the HIV I RT gene response for high level resistance against the NRTI's. Abacavi...

Promo Image

Abacavir's Trials and Tribulations

The thirteenth HIV drug is about to enter the market: After a day's worth of agonized debate, the FDA Antiviral Advisory Committee recommended approval of Glaxo Wellcome's abacavir (brand name: Ziagen) by a 7-2 vote. At Treatment Issues' press time, ...

Promo Image

Abacavir at Last

Glaxo Wellcome has finally announced the start of an expanded access program for its much heralded nucleoside analog abacavir. To qualify, they need only be "failing or intolerant to standard therapy and, in the judgment of the physician, unable to c...

Promo Image

1592: Where Are You? People With AIDS Demand Real Expanded Access for Glaxo's New AIDS Drug 1592

What is 1592?

Glaxo's new drug, 1592, may be as strong as some of the protease inhibitors. It's from a different family of AIDS drugs, called nucleosides. For people who have taken all the AIDS drugs -- 1592 may be their only hope.

GLAXO'S Underwhe...